Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817863 | 0.92 | HTR2A (0.46) | HTR2A | |
| SCHEMBL2817569 | 0.83 | HSD11B1 (0.43) | — | |
| SCHEMBL13841900 | 0.83 | HSD11B1 (0.43) | — | |
| SCHEMBL29929920 | 0.81 | P2RX3 (0.40) | HTR2A | |
| SCHEMBL2817891 | 0.81 | HTR2A (0.39) | HTR2A | |
| SCHEMBL2818863 | 0.78 | HTR2A (0.44) | HTR2A | |
| SCHEMBL12479425 | 0.78 | NR1H2 (0.34) | CCNT1CDK9 | |
| SCHEMBL3979322 | 0.75 | BCHE (0.41) | HTR2ACCNT1CDK9 | |
| SCHEMBL2819384 | 0.75 | BCHE (0.41) | HTR2ACCNT1CDK9 | |
| SCHEMBL2820222 | 0.75 | HSD11B1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155672-B1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-7528136-B2 | for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | SLC6A3, OPRL1, OPRK1 | HTR2A 121/4885CCNT1 2542/4885CDK9 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.